SMT202000693T1 - Intermedio sintetico utile nella preparazione di inibitori di c-met di triazolopiridina - Google Patents

Intermedio sintetico utile nella preparazione di inibitori di c-met di triazolopiridina

Info

Publication number: SMT202000693T1
Authority: SM; San Marino
Prior art keywords: triazolopyridine; preparation; synthetic intermediate; intermediate useful; met inhibitors
Prior art date: 2009-12-31

Application number

SM20200693T

Other languages

English (en)

Inventor

Wei-Guo Su

Guangxiu Dai

Hong Jia

Original Assignee

Hutchison Medipharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-31

Filing date

2010-12-30

Publication date

2021-01-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000693(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-12-30 Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd

2021-01-05 Publication of SMT202000693T1 publication Critical patent/SMT202000693T1/it

Links

239000003112 inhibitor Substances 0.000 title 1
OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)

SM20200693T 2009-12-31 2010-12-30 Intermedio sintetico utile nella preparazione di inibitori di c-met di triazolopiridina SMT202000693T1 (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN2009076321		2009-12-31
EP19151824.0A EP3511330B1 (en)	2009-12-31	2010-12-30	Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors

Publications (1)

Publication Number	Publication Date
SMT202000693T1 true SMT202000693T1 (it)	2021-01-05

Family

ID=44226181

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SM20200693T SMT202000693T1 (it)	2009-12-31	2010-12-30	Intermedio sintetico utile nella preparazione di inibitori di c-met di triazolopiridina
SM20220371T SMT202200371T1 (it)	2009-12-31	2010-12-30	Determinate triazolopirazine, loro composizioni e loro metodi d'uso
SM201500213T SMT201500213B (it)	2009-12-31	2015-09-09	Alcune triazolopirazine, loro composizioni e metodi d'uso

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SM20220371T SMT202200371T1 (it)	2009-12-31	2010-12-30	Determinate triazolopirazine, loro composizioni e loro metodi d'uso
SM201500213T SMT201500213B (it)	2009-12-31	2015-09-09	Alcune triazolopirazine, loro composizioni e metodi d'uso

Country Status (38)

Country	Link
US (9)	US8987269B2 (it)
EP (5)	EP2719699B1 (it)
JP (5)	JP5337313B2 (it)
KR (3)	KR101905350B1 (it)
CN (3)	CN106432225B (it)
AU (2)	AU2010338712B2 (it)
BR (1)	BR112012016129B1 (it)
CA (1)	CA2785749C (it)
CL (1)	CL2012001752A1 (it)
CO (1)	CO6612235A2 (it)
CU (1)	CU24167B1 (it)
CY (3)	CY1118250T1 (it)
DK (3)	DK3795573T3 (it)
DO (1)	DOP2012000188A (it)
EA (2)	EA030141B1 (it)
EC (1)	ECSP12012011A (it)
ES (4)	ES2726152T3 (it)
GT (1)	GT201200220A (it)
HR (3)	HRP20221090T1 (it)
HU (3)	HUE052828T2 (it)
IL (2)	IL220433B (it)
LT (1)	LT3795573T (it)
ME (1)	ME02211B (it)
MX (2)	MX386852B (it)
MY (1)	MY179933A (it)
NI (1)	NI201200118A (it)
NZ (1)	NZ601128A (it)
PE (3)	PE20130375A1 (it)
PH (1)	PH12012501355A1 (it)
PL (3)	PL3795573T3 (it)
PT (3)	PT2719699E (it)
RS (3)	RS61281B1 (it)
SG (1)	SG181781A1 (it)
SI (2)	SI2719699T1 (it)
SM (3)	SMT202000693T1 (it)
UA (1)	UA107822C2 (it)
WO (1)	WO2011079804A1 (it)
ZA (1)	ZA201205730B (it)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS61281B1 (sr) *	2009-12-31	2021-02-26	Hutchison Medipharma Ltd	Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
EP3450432A1 (en) *	2010-05-17	2019-03-06	Incozen Therapeutics Pvt. Ltd.	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CN103030654A (zh) *	2011-10-09	2013-04-10	济南赛文医药技术有限公司	一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) *	2011-11-22	2012-06-27	太仓市运通化工厂	一种2-溴丙醛的合成方法
AP3908A (en) *	2012-03-30	2016-11-24	Rhizen Pharmaceuticals Sa	Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
CA2776178A1 (en)	2012-04-05	2013-10-05	Hydro-Quebec	Ionic compounds
KR101745741B1 (ko)	2012-08-13	2017-06-12	한국화학연구원	신규한 트리아졸로 피라진 유도체 및 그의 용도
WO2014109414A1 (ja) *	2013-01-11	2014-07-17	富士フイルム株式会社	含窒素複素環化合物またはその塩
MX362247B (es)	2013-03-06	2019-01-09	Astrazeneca Ab	Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico.
CN103265468A (zh) *	2013-06-17	2013-08-28	连云港盛和生物科技有限公司	一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) *	2013-06-27	2014-12-31	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
AU2013402175B2 (en) *	2013-09-30	2017-09-07	Handok Inc.	Novel triazolopyrazine derivative and use thereof
CA2934667A1 (en) *	2013-12-26	2015-07-02	Ignyta, Inc.	Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP2016048495A (ja) *	2014-08-28	2016-04-07	京セラ株式会社	携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
AR106018A1 (es)	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en)	2015-08-26	2023-10-04	Achillion Pharmaceuticals, Inc.	Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amide compounds for treatment of immune and inflammatory disorders
CN106928232B (zh) *	2015-12-31	2019-07-09	上海医药集团股份有限公司	喹啉类化合物及其盐的晶型、制备方法、组合物与应用
GB201616116D0 (en)	2016-09-22	2016-11-09	Astrazeneca Ab	Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko)	2017-02-08	2018-08-17	에이비온 주식회사	트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
WO2018160891A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceutical, Inc.	Pharmaceutical compounds for treatment of medical disorders
KR102632860B1 (ko)	2017-03-01	2024-02-02	아칠리온 파르마세우티칼스 인코포레이티드	의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
WO2018160892A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceuticals, Inc.	Macrocyclic compounds for treatment of medical disorders
CN108570053A (zh) *	2017-03-13	2018-09-25	中国科学院上海药物研究所	五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko)	2017-08-16	2018-12-04	한국원자력의학원	트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu)	2018-07-13	2023-01-28	Richter Gedeon Nyrt	Spirokromán származékok
HU231414B1 (hu)	2018-07-13	2023-08-28	Richter Gedeon Nyrt.	Tiadiazin származékok
EP3846803A4 (en)	2018-09-06	2022-08-10	Achillion Pharmaceuticals, Inc.	Macrocyclic compounds for the treatment of medical disorders
US11814363B2 (en)	2018-09-06	2023-11-14	Achillion Pharmaceuticals, Inc.	Morphic forms of danicopan
IL281283B2 (en) *	2018-09-11	2024-01-01	Astrazeneca Ab	Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
EP3856164B1 (en)	2018-09-25	2024-08-07	Achillion Pharmaceuticals, Inc.	Morphic forms of complement factor d inhibitors
JP2022510501A (ja) *	2018-10-30	2022-01-26	リペアセラピューティクスインコーポレイテッド	化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法
US12258365B2 (en)	2018-12-14	2025-03-25	Beta Pharma, Inc.	Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof
BR112021011727A2 (pt)	2018-12-17	2021-08-31	Achillion Pharmaceuticals, Inc	Dosagem direcionada para o tratamento de distúrbios mediados do complemento
WO2020198062A1 (en)	2019-03-22	2020-10-01	Achillion Pharmaceuticals, Inc.	Pharmaceutical compounds for the treatment of complement mediated disorders
AU2020317381A1 (en) *	2019-07-22	2022-02-10	Repare Therapeutics Inc.	Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
CN115362162A (zh) *	2020-02-20	2022-11-18	艾其林医药公司	用于治疗补体因子d介导的障碍的杂芳基化合物
WO2021229605A1 (en) *	2020-05-14	2021-11-18	Dr. Reddy's Laboratories Limited	Process for preparation of savolitinib and its intermediates
WO2022066534A1 (en) *	2020-09-28	2022-03-31	Codexis, Inc.	Engineered biocatalysts and methods for synthesizing chiral amines
EP4263523A2 (en) *	2020-12-16	2023-10-25	IFM Due, Inc.	Compounds and compositions for treating conditions associated with sting activity
KR102659095B1 (ko)	2021-01-08	2024-04-19	에이비온 주식회사	트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) *	2021-05-31	2021-08-20	河南偶联生物科技有限公司	一种咪唑并[1,2-a]吡啶类化合物的合成方法
CN117897384A (zh)	2021-06-28	2024-04-16	缆图药品公司	Cdk2抑制剂
JP2025513560A (ja) *	2022-04-20	2025-04-24	エングレイルセラピューティクス，インコーポレーテッド	Ｇａｂａａ受容体モジュレーター塩、粒子、およびその使用
EP4551226A1 (en)	2022-07-08	2025-05-14	Astrazeneca AB	Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN119998281A (zh) *	2022-07-29	2025-05-13	贝勒医学院	神经营养受体酪氨酸激酶(ntrk)抑制剂及其使用方法
CN115611802B (zh) *	2022-12-02	2023-03-14	北京迪泰医药科技有限公司	一种3-乙酰基-2-氯吡啶的合成方法
CN120835885A (zh) *	2023-01-04	2025-10-24	缆图药品公司	Cdk2抑制剂
GB202300923D0 (en) *	2023-01-20	2023-03-08	Macfarlan Smith Ltd	Novel polymorphic forms of savolitinib
WO2024263860A1 (en) *	2023-06-22	2024-12-26	Ifm Due, Inc.	Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3989816A (en)	1975-06-19	1976-11-02	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en)	1980-04-04	1984-04-24	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) *	1996-12-05	1999-11-02	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
CA2333040A1 (en) *	1998-05-26	1999-12-02	Merck & Co., Inc.	Imidazopyridine thrombin inhibitors
JP2000119250A (ja) *	1998-08-11	2000-04-25	Takeda Chem Ind Ltd	環状アミド化合物、その製造法、中間体及び除草剤
WO2004092177A1 (en)	2003-04-09	2004-10-28	Biogen Idec Ma Inc.	Triazolopyrazines and methods of making and using the same
JP2007516180A (ja) *	2003-07-02	2007-06-21	スゲン，インコーポレイティド	ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
US7122548B2 (en)	2003-07-02	2006-10-17	Sugen, Inc.	Triazolotriazine compounds and uses thereof
WO2005028480A2 (en)	2003-09-03	2005-03-31	Neurogen Corporation	5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
EP2264033A1 (en)	2004-07-27	2010-12-22	SGX Pharmaceuticals, Inc.	3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS
JP2008509987A (ja)	2004-08-18	2008-04-03	ファルマシアアンドアップジョンカンパニーリミテッドライアビリティカンパニー	トリアゾロピリジン化合物
CN101119996A (zh) *	2005-02-16	2008-02-06	阿斯利康(瑞典)有限公司	化学化合物
WO2006087538A1 (en) *	2005-02-16	2006-08-24	Astrazeneca Ab	Chemical compounds
CA2630884A1 (en)	2005-11-30	2007-06-07	Vertex Pharmaceuticals Incorporated	Inhibitors of c-met and uses thereof
HUE030390T2 (en)	2005-12-21	2017-05-29	Janssen Pharmaceutica Nv	Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl)	2006-05-11	2007-11-20	Pfizer Prod Inc	Triazoolpyrazinederivaten.
EP2032578A2 (en)	2006-05-30	2009-03-11	Pfizer Products Incorporated	Triazolopyridazine derivatives
PE20080403A1 (es)	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
JP2010500365A (ja)	2006-08-07	2010-01-07	インサイト・コーポレイション	キナーゼ阻害剤としてのトリアゾロトリアジン
WO2008036272A1 (en)	2006-09-18	2008-03-27	Vertex Pharmaceuticals Incorporated	HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
CA2667428A1 (en)	2006-10-23	2008-05-02	Sgx Pharmaceuticals, Inc.	Bicyclic triazoles as protein kinase modulators
KR101083177B1 (ko) *	2006-10-23	2011-11-11	에스지엑스 파마슈티컬스, 인코포레이티드	트리아졸로-피리다진 단백질 키나제 조정제
ES2560435T3 (es)	2006-11-22	2016-02-19	Incyte Holdings Corporation	Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
JP4785881B2 (ja) *	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
CN101679436A (zh)	2007-04-10	2010-03-24	Sgx药品公司	稠环杂环激酶调节剂
WO2008138842A1 (en)	2007-05-10	2008-11-20	Galapagos N.V.	Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
PA8792501A1 (es)	2007-08-09	2009-04-23	Sanofi Aventis	Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
EP2285216A4 (en) *	2008-02-21	2012-09-19	Sequoia Pharmaceuticals Inc	HIV PROTEASE INHIBITOR AND COMBINED CYTOCHROME P450 INHIBITOR
PE20091468A1 (es)	2008-02-28	2009-10-22	Novartis Ag	DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
US8691838B2 (en)	2008-05-22	2014-04-08	Amgen Inc.	Heterocycles as protein kinase inhibitors
DE102008037790A1 (de)	2008-08-14	2010-02-18	Merck Patent Gmbh	Bicyclische Triazolderivate
UY32049A (es)	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
EA201200260A1 (ru) *	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002179A (es) *	2009-08-20	2012-03-16	Novartis Ag	Compuestos heterociclicos de oxima.
RS61281B1 (sr) *	2009-12-31	2021-02-26	Hutchison Medipharma Ltd	Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
EP3450432A1 (en)	2010-05-17	2019-03-06	Incozen Therapeutics Pvt. Ltd.	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases

2010
- 2010-12-30 RS RS20201567A patent/RS61281B1/sr unknown
- 2010-12-30 RS RS20150584A patent/RS54217B1/sr unknown
- 2010-12-30 SM SM20200693T patent/SMT202000693T1/it unknown
- 2010-12-30 HR HRP20221090TT patent/HRP20221090T1/hr unknown
- 2010-12-30 BR BR112012016129-6A patent/BR112012016129B1/pt active IP Right Grant
- 2010-12-30 KR KR1020177022937A patent/KR101905350B1/ko active Active
- 2010-12-30 HU HUE19151824A patent/HUE052828T2/hu unknown
- 2010-12-30 CN CN201610432059.7A patent/CN106432225B/zh active Active
- 2010-12-30 JP JP2012546344A patent/JP5337313B2/ja active Active
- 2010-12-30 MY MYPI2012002974A patent/MY179933A/en unknown
- 2010-12-30 AU AU2010338712A patent/AU2010338712B2/en active Active
- 2010-12-30 PE PE2012000903A patent/PE20130375A1/es not_active Application Discontinuation
- 2010-12-30 NZ NZ601128A patent/NZ601128A/en unknown
- 2010-12-30 HU HUE13198224A patent/HUE025504T2/en unknown
- 2010-12-30 ME MEP-2015-150A patent/ME02211B/me unknown
- 2010-12-30 LT LTEP20199091.8T patent/LT3795573T/lt unknown
- 2010-12-30 CN CN201080065014.1A patent/CN102906092B/zh active Active
- 2010-12-30 US US13/501,222 patent/US8987269B2/en active Active
- 2010-12-30 CU CU20120101A patent/CU24167B1/es active IP Right Grant
- 2010-12-30 PE PE2020001800A patent/PE20211094A1/es unknown
- 2010-12-30 RS RS20220854A patent/RS63612B1/sr unknown
- 2010-12-30 PL PL20199091.8T patent/PL3795573T3/pl unknown
- 2010-12-30 CA CA2785749A patent/CA2785749C/en active Active
- 2010-12-30 CN CN201610437304.3A patent/CN106117248B/zh active Active
- 2010-12-30 PE PE2016000292A patent/PE20160588A1/es unknown
- 2010-12-30 KR KR1020147010967A patent/KR101771299B1/ko active Active
- 2010-12-30 DK DK20199091.8T patent/DK3795573T3/da active
- 2010-12-30 PH PH1/2012/501355A patent/PH12012501355A1/en unknown
- 2010-12-30 DK DK13198224.1T patent/DK2719699T3/en active
- 2010-12-30 HU HUE20199091A patent/HUE059696T2/hu unknown
- 2010-12-30 EP EP13198224.1A patent/EP2719699B1/en active Active
- 2010-12-30 PT PT131982241T patent/PT2719699E/pt unknown
- 2010-12-30 MX MX2016001733A patent/MX386852B/es unknown
- 2010-12-30 EP EP19151824.0A patent/EP3511330B1/en active Active
- 2010-12-30 ES ES15170608T patent/ES2726152T3/es active Active
- 2010-12-30 DK DK19151824.0T patent/DK3511330T3/da active
- 2010-12-30 EP EP15170608.2A patent/EP2966075B1/en active Active
- 2010-12-30 PL PL13198224T patent/PL2719699T3/pl unknown
- 2010-12-30 SI SI201031021T patent/SI2719699T1/sl unknown
- 2010-12-30 UA UAA201208929A patent/UA107822C2/ru unknown
- 2010-12-30 EP EP20199091.8A patent/EP3795573B1/en active Active
- 2010-12-30 KR KR1020127019509A patent/KR101434766B1/ko active Active
- 2010-12-30 PT PT201990918T patent/PT3795573T/pt unknown
- 2010-12-30 SG SG2012044830A patent/SG181781A1/en unknown
- 2010-12-30 ES ES19151824T patent/ES2840454T3/es active Active
- 2010-12-30 EA EA201691461A patent/EA030141B1/ru not_active IP Right Cessation
- 2010-12-30 ES ES20199091T patent/ES2927146T3/es active Active
- 2010-12-30 SM SM20220371T patent/SMT202200371T1/it unknown
- 2010-12-30 MX MX2012007756A patent/MX336996B/es active IP Right Grant
- 2010-12-30 WO PCT/CN2010/080499 patent/WO2011079804A1/en not_active Ceased
- 2010-12-30 PL PL19151824T patent/PL3511330T3/pl unknown
- 2010-12-30 ES ES13198224.1T patent/ES2546635T3/es active Active
- 2010-12-30 PT PT191518240T patent/PT3511330T/pt unknown
- 2010-12-30 EA EA201200951A patent/EA025466B1/ru not_active IP Right Cessation
- 2010-12-30 SI SI201032046T patent/SI3511330T1/sl unknown
- 2010-12-30 EP EP10840591.1A patent/EP2519524A4/en not_active Withdrawn
2012
- 2012-04-10 US US13/501,224 patent/US8507487B2/en active Active
- 2012-06-14 IL IL220433A patent/IL220433B/en active IP Right Grant
- 2012-06-26 CL CL2012001752A patent/CL2012001752A1/es unknown
- 2012-06-28 GT GT201200220A patent/GT201200220A/es unknown
- 2012-06-29 CO CO12109937A patent/CO6612235A2/es not_active Application Discontinuation
- 2012-06-29 NI NI201200118A patent/NI201200118A/es unknown
- 2012-06-29 DO DO2012000188A patent/DOP2012000188A/es unknown
- 2012-06-29 EC EC2012012011A patent/ECSP12012011A/es unknown
- 2012-07-30 ZA ZA2012/05730A patent/ZA201205730B/en unknown
2013
- 2013-06-11 JP JP2013122502A patent/JP2013209418A/ja active Pending
2015
- 2015-01-21 US US14/601,674 patent/US20150368271A1/en not_active Abandoned
- 2015-06-23 AU AU2015203480A patent/AU2015203480B2/en active Active
- 2015-07-16 IL IL239997A patent/IL239997A/en active IP Right Grant
- 2015-09-08 HR HRP20150952TT patent/HRP20150952T1/hr unknown
- 2015-09-09 SM SM201500213T patent/SMT201500213B/it unknown
- 2015-09-17 CY CY20151100816T patent/CY1118250T1/el unknown
2016
- 2016-04-04 JP JP2016074893A patent/JP6194046B2/ja active Active
- 2016-10-14 US US15/293,722 patent/US9956218B2/en active Active
2017
- 2017-08-10 JP JP2017155493A patent/JP6486999B2/ja active Active
2018
- 2018-04-04 US US15/945,324 patent/US10512645B2/en active Active
2019
- 2019-02-20 JP JP2019028197A patent/JP6647434B2/ja active Active
- 2019-11-08 US US16/678,091 patent/US10946014B2/en active Active
2020
- 2020-12-17 HR HRP20202017TT patent/HRP20202017T1/hr unknown
- 2020-12-21 CY CY20201101206T patent/CY1123777T1/el unknown
2021
- 2021-02-03 US US17/248,688 patent/US11896592B2/en active Active
2022
- 2022-09-15 CY CY20221100615T patent/CY1125550T1/el unknown
2023
- 2023-12-13 US US18/538,151 patent/US20240139182A1/en not_active Abandoned
2024
- 2024-05-28 US US18/676,172 patent/US20250099462A1/en active Pending

Also Published As

Publication number	Publication date
AU2010338712B2 (en)	2015-04-02
SG181781A1 (en)	2012-07-30
ES2546635T3 (es)	2015-09-25
AU2015203480B2 (en)	2017-10-26
US8507487B2 (en)	2013-08-13
ME02211B (me)	2016-02-20
JP2018009004A (ja)	2018-01-18
PE20130375A1 (es)	2013-04-10
SI3511330T1 (sl)	2021-01-29
US20180263977A1 (en)	2018-09-20
UA107822C2 (xx)	2015-02-25
JP2016155848A (ja)	2016-09-01
SI2719699T1 (sl)	2015-12-31
EA201200951A1 (ru)	2013-09-30
EP3511330A1 (en)	2019-07-17
RS54217B1 (sr)	2015-12-31
MX2012007756A (es)	2012-11-06
EP2519524A1 (en)	2012-11-07
EP2966075A1 (en)	2016-01-13
JP6486999B2 (ja)	2019-03-20
RS61281B1 (sr)	2021-02-26
EP2966075B1 (en)	2019-02-27
CU24167B1 (es)	2016-03-31
HUE052828T2 (hu)	2021-05-28
HRP20221090T1 (hr)	2022-11-25
AU2010338712A1 (en)	2012-07-12
JP5337313B2 (ja)	2013-11-06
ES2726152T3 (es)	2019-10-02
EA030141B1 (ru)	2018-06-29
AU2015203480A1 (en)	2015-07-16
KR20170098324A (ko)	2017-08-29
KR101434766B1 (ko)	2014-08-26
US20240139182A1 (en)	2024-05-02
EA201691461A1 (ru)	2017-01-30
CY1118250T1 (el)	2017-06-28
EP2719699A1 (en)	2014-04-16
CN106117248B (zh)	2019-01-22
US20150368271A1 (en)	2015-12-24
PE20160588A1 (es)	2016-07-09
EP2519524A4 (en)	2013-07-03
US20210154192A1 (en)	2021-05-27
PL2719699T3 (pl)	2016-01-29
IL239997A (en)	2017-11-30
CY1123777T1 (el)	2022-03-24
ECSP12012011A (es)	2012-10-30
JP2013516393A (ja)	2013-05-13
PH12012501355A1 (en)	2012-12-17
IL239997A0 (en)	2015-08-31
GT201200220A (es)	2014-12-22
KR20120125261A (ko)	2012-11-14
CN106432225A (zh)	2017-02-22
CU20120101A7 (es)	2012-10-15
CA2785749A1 (en)	2011-07-07
KR20140059307A (ko)	2014-05-15
NI201200118A (es)	2013-01-24
PE20211094A1 (es)	2021-06-14
SMT202200371T1 (it)	2022-11-18
WO2011079804A1 (en)	2011-07-07
PL3795573T3 (pl)	2022-11-21
HRP20150952T1 (hr)	2015-10-09
MY179933A (en)	2020-11-19
ES2927146T3 (es)	2022-11-02
JP2019108345A (ja)	2019-07-04
CO6612235A2 (es)	2013-02-01
ZA201205730B (en)	2016-01-27
IL220433B (en)	2018-01-31
CL2012001752A1 (es)	2013-01-25
EP2719699B1 (en)	2015-07-08
SMT201500213B (it)	2015-10-30
DOP2012000188A (es)	2012-12-31
DK3795573T3 (da)	2022-09-19
US8987269B2 (en)	2015-03-24
US20120245178A1 (en)	2012-09-27
CN102906092B (zh)	2016-08-03
DK2719699T3 (en)	2015-08-24
US10512645B2 (en)	2019-12-24
PT3511330T (pt)	2020-12-24
EP3511330B1 (en)	2020-09-30
MX336996B (es)	2016-02-09
JP6647434B2 (ja)	2020-02-14
CY1125550T1 (el)	2026-02-25
RS63612B1 (sr)	2022-10-31
US20170027934A1 (en)	2017-02-02
KR101905350B1 (ko)	2018-11-30
JP6194046B2 (ja)	2017-09-06
HUE059696T2 (hu)	2022-12-28
EA025466B1 (ru)	2016-12-30
US11896592B2 (en)	2024-02-13
PL3511330T3 (pl)	2021-04-19
CN106117248A (zh)	2016-11-16
US20120264739A1 (en)	2012-10-18
US20250099462A1 (en)	2025-03-27
MX386852B (es)	2025-03-19
NZ601128A (en)	2014-12-24
HK1194071A1 (en)	2014-10-10
HK1216880A1 (en)	2016-12-09
CN102906092A (zh)	2013-01-30
US9956218B2 (en)	2018-05-01
JP2013209418A (ja)	2013-10-10
CN106432225B (zh)	2019-02-19
ES2840454T3 (es)	2021-07-06
PT2719699E (pt)	2015-09-30
EP3795573A1 (en)	2021-03-24
HRP20202017T1 (hr)	2021-02-19
DK3511330T3 (da)	2020-12-21
EP3795573B1 (en)	2022-07-06
US10946014B2 (en)	2021-03-16
BR112012016129B1 (pt)	2020-11-03
CA2785749C (en)	2017-11-28
KR101771299B1 (ko)	2017-08-24
HUE025504T2 (en)	2016-02-29
US20200179377A1 (en)	2020-06-11
LT3795573T (lt)	2022-11-10
PT3795573T (pt)	2022-09-15
BR112012016129A2 (pt)	2016-05-31

Publication	Publication Date	Title
HUE052828T2 (hu)	2021-05-28	Szintetikus köztitermék, amely triazolopiridin c-Met gátlók elõállítására használható
LT3511330T (lt)	2021-03-25	Sintetinis tarpinis junginys, naudotinas triazolpiridino c-met inhibitorių paruošimui
IL220091A0 (en)	2012-09-24	Pcsk9 antagonists
PL2575504T3 (pl)	2019-05-31	Kompozycja odżywcza wykazująca właściwości immunologiczne
ZA201204266B (en)	2014-11-26	Antibody formulation
ZA201106503B (en)	2012-11-28	Antibody formulation
ZA201202906B (en)	2012-12-27	Novel naphthyridine derivatives and the use thereof as kinase inhibitors
ZA201203242B (en)	2013-07-31	Antibody formulation
EP2600760A4 (en)	2014-08-20	IMPROVED LARYNGOSCOPY
ZA201303811B (en)	2014-04-30	Triazolopyridine compounds
ZA201107963B (en)	2015-12-23	Dentifrice composition
ZA201303661B (en)	2018-12-19	Cleansing composition
GB0907003D0 (en)	2009-06-03	Formulation
EP2620160A4 (en)	2014-05-07	COMPOSITIONS FOR ORAL ADMINISTRATION
IL219603A0 (en)	2012-07-31	Imidazopyridine derivatives
EP2444401A4 (en)	2012-11-07	NEW IMIDAZOPYRIDINE COMPOUND
GB0911213D0 (en)	2009-08-12	Formulation
GB0907410D0 (en)	2009-06-10	Formulation
GB201001022D0 (en)	2010-03-10	Play article
GB0910593D0 (en)	2009-07-29	Carpet rail
GB201005758D0 (en)	2010-05-19	Buffet train
GB0906291D0 (en)	2009-05-20	Formulation
GB0902472D0 (en)	2009-04-01	Formulation
GB201004957D0 (en)	2010-05-12	Ergo puregrip Cue
GB201010378D0 (en)	2010-08-04	Cleaning composition